Objective: To study the effects of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Erlotinib on curative effects and survival rate of non-small cell lung cancer (NSCLC) patients with different mutants of EGFR gene. Methods: 72 cases of advanced NSCLC patients with EGFR positive mutations were divided into study group (n=33) and control group (n=39) according to mutations in exon 19 or 21 of EGFR gene. All the patients were treated with Erlotinib Hydrochloride Tablets orally till disease progression or death. The short-term clinical effective rate, time to progression (TTP) and one-year survival rate of patients in 2 groups were compared. Results: The short-term clinical effective rate, one-year survival rate and average TTP of patients in study group were all obviously higher than control group (P<0.05). Conclusions: The curative effects and survival rate of NSCLC patients with exon 19 mutation were better than NSCLC patients with exon 21 mutation when treating NSCLC with EGFR-TKI Erlotinib. Which suggests that detection of different mutants of EGFR gene may be helpful in formulating individualized therapeutic regimen and predicting the therapeutic effect of EGFR-TKI Erlotinib.

Objective: To analyze the relationships between apolipoprotein B/A1, glycosylated hemoglobin (HbA1c) level and venous thrombolytic outcome in acute cerebral infarction patients. Methods: 76 acute cerebral infarction patients were all treated with recombinant tissue plasminogen activator (rt-PA) venous thrombolysis, and the patients were divided into ineffective group (n=27) and effective group (n=49) according to improvement of NIHSS score before and after thrombolysis. The blood glucose, blood lipid, HbA1c and other indicators of all the patients were detected. Results: The HbA1c, ApoB and ApoB/A1 of patients in effective group were significantly lower than ineffective group, the ApoA1 was significantly higher (P<0.05). Logistic regression analysis showed that age, HbA1c and ApoB/A1 were independent risk factors for thrombolytic outcome (P<0.05). Conclusions: ApoB/A1 and HbA1c may has certain predicting value for thrombolytic outcome in acute cerebral infarction patients at early stage.

ObjectiveTo investigate the effects of type H hypertension on prognosis of intravenous thrombolysis in patients with acute cerebral infarction.Methods182 cases of acute cerebral infarction patients receiving intravenous thrombolysis with at-PA were divided into type H hypertension+cerebral infarction group (group A), hypertension+cerebral infarction group (group B), hyperhomocysteinemia+cerebral infarction group (group C) and cerebral infarction group without HHcy and hypertension (group D). The blood pressure, serum Hcy level and prognosis of patients in 4 groups were compared; And the influencing factors of poor prognosis after thrombolytic therapy were also analyzed.ResultsThe systolic pressure, serum Hcy level of patients in group A were obviously higher than group B, C, D (P<0.05). Compared with other 3 groups, the incidence of poor prognosis of group A was the highest (P<0.05). Logistic regression analysis showed that age, Hcy and systolic pressure are independent risk factors of recent poor prognosis of intravenous thrombolysis after acute cerebral infarction.ConclusionsType H hypertension is an important risk factor for the prognosis of intravenous thrombolysis in patients with acute cerebral infarction.